Comparative Prognostic Significance of CEA and CA15-3 in Breast Cancer
Article Sidebar
Main Article Content
Abstract
Breast cancer is a leading cause of cancer-related mortality worldwide, particularly among women. Thus, it is critical to have reliable biomarkers for prognosis and metastasis detection. This retrospective study compared the prognostic utility of serum tumour markers CEA and CA15-3 in 117 female breast cancer patients admitted to Lattakia University Hospital. Patients were stratified by histopathological type, molecular subtype, tumour stage, size, and metastasis location. Patients were stratified by histopathological type, molecular subtype, tumour stage, size, and metastasis location. Elevated CA15-3 levels were significantly associated with advanced tumour stage (P<0.05) and metastatic disease (P<0.0001), but not with specific metastatic sites, tumour size, or molecular subtype (P>0.05). In contrast, while CEA levels were not significantly elevated in advanced tumour stages, they correlated with larger tumour size (P<0.05) and metastasis (P<0.001), particularly liver metastasis (P<0.05).Kaplan-Meier analysis revealed that elevated CEA (>5 ng/mL) was significantly associated with worse 5-year overall survival (27% vs. 68%, P<0.001), whereas CA15-3 (>35 IU/mL) was not (50% vs. 75%, P>0.05). These findings highlight CEA’s potential as a prognostic biomarker, particularly for liver metastasis. The controversial results of our study support using CEA in clinical surveillance for breast cancer.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Ferlay J, E.M., Lam F, Laversanne M, Colombet M, Mery L, Piٌeros M, Znaor A, Soerjomataram I, Bray Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2024. URL: https://gco.iarc.fr/en
Wang, J. and S.-G. Wu, Breast cancer: an overview of current therapeutic strategies, challenges, and perspectives. Breast Cancer: Targets and Therapy, 2023: p. 721-730. DOI: https://doi.org/10.2147/BCTT.S432526
Organization, W.H., Global cancer burden growing, amidst mounting need for services. World Health Organization: Geneva, Switzerland, 2024. URL: http://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services
Mouabbi, J.A., et al., Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast cancer research and treatment, 2022. 193(2): p. 253-264. DOI: https://doi.org/10.1007/s10549-022-06572-w
Zhao, H., The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast. Breast Cancer, 2021. 28: p. 187-195. DOI: https://doi.org/10.1007/s12282-020-01146-4
Teichgraeber, D.C., M.S. Guirguis, and G.J. Whitman, Breast cancer staging: Updates in the AJCC cancer staging manual, and current challenges for radiologists, from the AJR special series on cancer staging. American Journal of Roentgenology, 2021. 217(2): p. 278-290. DOI: https://doi.org/10.2214/AJR.20.25223
Kim, E.J., et al., Assessment of the prognostic staging system of American Joint Committee on Cancer 8th Edition for breast cancer: comparisons with the conventional anatomic staging system. Journal of Breast Cancer, 2020. 23(1): p. 59.
DOI: https://doi.org/10.4048/jbc.2020.23.e9
Menon, G., F.M. Alkabban, and T. Ferguson, Breast Cancer, in StatPearls. 2025: Treasure Island (FL). URL: https://www.ncbi.nlm.nih.gov/books/NBK482286/.
Łukasiewicz, S., et al., Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers, 2021. 13(17): p. 4287. DOI: https://doi.org/10.3390/cancers13174287
Smolarz, B., A.Z. Nowak, and H. Romanowicz, Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature). Cancers, 2022. 14(10): p. 2569. DOI: https://doi.org/10.3390/cancers14102569
Sheva, K., et al., Molecular changes in breast cancer induced by radiation therapy. International Journal of Radiation Oncology* Biology* Physics, 2024. DOI: https://doi.org/10.1016/j.ijrobp.2024.03.019
Zhou, Y., et al., Tumour biomarkers for diagnosis, prognosis and targeted therapy. Signal transduction and targeted therapy, 2024. 9(1): p. 132. DOI: https://doi.org/10.1038/s41392-024-01823-2
Seale, K.N. and K.H. Tkaczuk, Circulating biomarkers in breast cancer. Clinical breast cancer, 2022. 22(3): p. e319-e331.
DOI: https://doi.org/10.1016/j.clbc.2021.09.006
Hall, C., et al., A review of the role of carcinoembryonic antigen in clinical practice. Annals of Coloproctology, 2019. 35(6): p. 294.
DOI: https://doi.org/10.3393/ac.2019.11.13
Yang, Y., et al., Serum carcinoembryonic antigen elevation in benign lung diseases. Scientific Reports, 2021. 11(1): p. 19044.
DOI: https://doi.org/10.1038/s41598-021-98513-8
Jeong, S., et al., Current immunoassay methods and their applications to clinically used biomarkers of breast cancer. Clinical biochemistry, 2020. 78: p. 43-57. DOI: https://doi.org/10.1016/j.clinbiochem.2020.01.009
Henry, N.L., et al., Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. Journal of Clinical Oncology, 2022. 40(27): p. 3205-3221. DOI: https://doi.org/10.1200/JCO.22.01063
Ryu, J.M., et al., Prognostic impact of elevation of cancer antigen 15 3 (CA15-3) in patients with early breast cancer with normal serum CA15-3 level. Journal of Breast Cancer, 2023. 26(2): p. 126. DOI: https://doi.org/10.4048/jbc.2023.26.e17
Uygur, M.M. and M. Gümüş, The utility of serum tumour markers CEA and CA 15–3 for breast cancer prognosis and their association with clinicopathological parameters. Cancer Treatment and Research Communications, 2021. 28: p. 100402.
DOI: https://doi.org/10.1016/j.ctarc.2021.100402
Altimmime, B.A. and F.A. Rashid, Evaluation of CXCL12, carbohydrate antigen CA15.3, calcium and parathyroid hormone as potential biomarkers for bone metastasis in patients with breast cancer. World Academy of Sciences Journal, 2024. 7(2): p. 21.
DOI: https://doi.org/10.3892/wasj.2024.309
Fakhari, A., et al., Correlation of cancer antigen 15 3 (CA15-3) serum level and bony metastases in breast cancer patients. Medical Journal of the Islamic Republic of Iran, 2019. 33: p. 142. DOI: https://doi.org/10.34171/mjiri.33.142
Khodabakhsh, F., et al., Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signalling. Cancer Cell International, 2021. 21(1): p. 200. DOI: https://doi.org/10.1186/s12935-021-01899-8
Sinha, P., et al., Correlation of Ca15-3 and CEA in different molecular subtypes of metastatic breast cancer. International Journal of Research and Review, 2019. 6(8): p. 203-8. URL: https://www.academia.edu/download/63584640/IJRR003020200610-87854-x7rgct.pdf
Salih, M.J., L. Al-Mansouri, and H.M. Hasson, Exploring the Prognostic Value of CS15-3 Tumour Marker in Breast Cancer Recurrence. Asian Pacific Journal of Cancer Prevention: APJCP, 2024. 25(1): p. 229. DOI: https://doi.org/10.31557/APJCP.2024.25.1.229
Dyachenko, E.I. and L.V. Bel’skaya, Salivary transmembrane mucins of the MUC1 family (CA 15-3, CA 27.29, MCA) in breast cancer: the effect of human epidermal growth factor receptor 2 (HER2). Cancers, 2024. 16(20): p. 3461. DOI: https://doi.org/10.3390/cancers16203461
Shao, Y., et al., Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PloS one, 2015. 10(7): p. e0133830. DOI: https://doi.org/10.1371/journal.pone.0133830
Luan, Y., et al., Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: A retrospective case-control study. Journal of Bio-X Research, 2021. 4(02): p. 60-66. DOI: https://doi.org/10.1097/JBR.0000000000000093
Yuan, Q., et al., The role of macrophages in liver metastasis: mechanisms and therapeutic prospects. Frontiers in Immunology, 2025. 16: p. 1542197. DOI: https://doi.org/10.3389/fimmu.2025.1542197
Lee, J.H. and S.-W. Lee, The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. Gastroenterology research and practice, 2017. 2017(1): p. 7521987. DOI: https://doi.org/10.1155/2017/7521987
Imamura, M., et al., Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World journal of surgical oncology, 2018. 16: p. 1-11. DOI: https://doi.org/10.1186/s12957-018-1325-6